DANONE (BSN.DE) Fundamental Analysis & Valuation

FRA:BSN • FR0000120644

Current stock price

67.16 EUR
-0.76 (-1.12%)
Last:

This BSN.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BSN.DE Profitability Analysis

1.1 Basic Checks

  • In the past year BSN was profitable.
  • BSN had a positive operating cash flow in the past year.
  • BSN had positive earnings in each of the past 5 years.
  • BSN had a positive operating cash flow in each of the past 5 years.
BSN.DE Yearly Net Income VS EBIT VS OCF VS FCFBSN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

1.2 Ratios

  • The Return On Assets of BSN (4.03%) is comparable to the rest of the industry.
  • BSN has a Return On Equity of 10.73%. This is comparable to the rest of the industry: BSN outperforms 59.02% of its industry peers.
  • The Return On Invested Capital of BSN (7.75%) is better than 65.57% of its industry peers.
  • BSN had an Average Return On Invested Capital over the past 3 years of 7.51%. This is in line with the industry average of 7.00%.
  • The 3 year average ROIC (7.51%) for BSN is below the current ROIC(7.75%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.03%
ROE 10.73%
ROIC 7.75%
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
BSN.DE Yearly ROA, ROE, ROICBSN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • BSN has a Profit Margin of 6.66%. This is in the better half of the industry: BSN outperforms 63.93% of its industry peers.
  • In the last couple of years the Profit Margin of BSN has declined.
  • BSN has a Operating Margin of 13.43%. This is amongst the best in the industry. BSN outperforms 85.25% of its industry peers.
  • In the last couple of years the Operating Margin of BSN has remained more or less at the same level.
  • Looking at the Gross Margin, with a value of 50.62%, BSN belongs to the top of the industry, outperforming 85.25% of the companies in the same industry.
  • BSN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 13.43%
PM (TTM) 6.66%
GM 50.62%
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
BSN.DE Yearly Profit, Operating, Gross MarginsBSN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BSN.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BSN is still creating some value.
  • The number of shares outstanding for BSN has been reduced compared to 1 year ago.
  • Compared to 5 years ago, BSN has less shares outstanding
  • BSN has a worse debt/assets ratio than last year.
BSN.DE Yearly Shares OutstandingBSN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
BSN.DE Yearly Total Debt VS Total AssetsBSN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • BSN has an Altman-Z score of 2.36. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
  • BSN has a Altman-Z score (2.36) which is in line with its industry peers.
  • BSN has a debt to FCF ratio of 5.29. This is a neutral value as BSN would need 5.29 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 5.29, BSN is in the better half of the industry, outperforming 68.85% of the companies in the same industry.
  • A Debt/Equity ratio of 0.73 indicates that BSN is somewhat dependend on debt financing.
  • BSN has a worse Debt to Equity ratio (0.73) than 62.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 5.29
Altman-Z 2.36
ROIC/WACC1.22
WACC6.33%
BSN.DE Yearly LT Debt VS Equity VS FCFBSN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • BSN has a Current Ratio of 0.90. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of BSN (0.90) is worse than 78.69% of its industry peers.
  • A Quick Ratio of 0.75 indicates that BSN may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.75, BSN perfoms like the industry average, outperforming 40.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.75
BSN.DE Yearly Current Assets VS Current LiabilitesBSN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BSN.DE Growth Analysis

3.1 Past

  • BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.68%.
  • The Earnings Per Share has been growing slightly by 2.61% on average over the past years.
  • BSN shows a decrease in Revenue. In the last year, the revenue decreased by -0.34%.
  • Measured over the past years, BSN shows a small growth in Revenue. The Revenue has been growing by 2.93% on average per year.
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.81% on average over the next years.
  • The Revenue is expected to grow by 4.25% on average over the next years.
EPS Next Y7.51%
EPS Next 2Y7.63%
EPS Next 3Y7.85%
EPS Next 5Y7.81%
Revenue Next Year2.65%
Revenue Next 2Y3.28%
Revenue Next 3Y3.54%
Revenue Next 5Y4.25%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BSN.DE Yearly Revenue VS EstimatesBSN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
BSN.DE Yearly EPS VS EstimatesBSN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

4

4. BSN.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 17.67, which indicates a rather expensive current valuation of BSN.
  • BSN's Price/Earnings ratio is in line with the industry average.
  • When comparing the Price/Earnings ratio of BSN to the average of the S&P500 Index (24.89), we can say BSN is valued slightly cheaper.
  • Based on the Price/Forward Earnings ratio of 16.44, the valuation of BSN can be described as correct.
  • BSN's Price/Forward Earnings is on the same level as the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, BSN is valued a bit cheaper.
Industry RankSector Rank
PE 17.67
Fwd PE 16.44
BSN.DE Price Earnings VS Forward Price EarningsBSN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as BSN.
  • BSN's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BSN is cheaper than 63.93% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.79
EV/EBITDA 9.25
BSN.DE Per share dataBSN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSN does not grow enough to justify the current Price/Earnings ratio.
  • BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.35
PEG (5Y)6.76
EPS Next 2Y7.63%
EPS Next 3Y7.85%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. BSN.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 3.32%, BSN has a reasonable but not impressive dividend return.
  • BSN's Dividend Yield is a higher than the industry average which is at 3.59.
  • Compared to an average S&P500 Dividend Yield of 1.89, BSN pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.32%

5.2 History

  • The dividend of BSN has a limited annual growth rate of 0.46%.
Dividend Growth(5Y)0.46%
Div Incr Years3
Div Non Decr Years4
BSN.DE Yearly Dividends per shareBSN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

5.3 Sustainability

  • BSN pays out 75.94% of its income as dividend. This is not a sustainable payout ratio.
  • The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP75.94%
EPS Next 2Y7.63%
EPS Next 3Y7.85%
BSN.DE Yearly Income VS Free CF VS DividendBSN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
BSN.DE Dividend Payout.BSN.DE Dividend Payout, showing the Payout Ratio.BSN.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

BSN.DE Fundamentals: All Metrics, Ratios and Statistics

DANONE

FRA:BSN (3/27/2026, 7:00:00 PM)

67.16

-0.76 (-1.12%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)02-20
Earnings (Next)04-22
Inst Owners53.9%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap45.76B
Revenue(TTM)27.28B
Net Income(TTM)1.82B
Analysts75.15
Price Target80.77 (20.27%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.32%
Yearly Dividend2.15
Dividend Growth(5Y)0.46%
DP75.94%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.1%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.02%
EPS NY rev (3m)-2.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)-0.77%
Valuation
Industry RankSector Rank
PE 17.67
Fwd PE 16.44
P/S 1.68
P/FCF 16.79
P/OCF 12.11
P/B 2.7
P/tB N/A
EV/EBITDA 9.25
EPS(TTM)3.8
EY5.66%
EPS(NY)4.09
Fwd EY6.08%
FCF(TTM)4
FCFY5.95%
OCF(TTM)5.55
OCFY8.26%
SpS40.04
BVpS24.83
TBVpS-9.13
PEG (NY)2.35
PEG (5Y)6.76
Graham Number46.07
Profitability
Industry RankSector Rank
ROA 4.03%
ROE 10.73%
ROCE 12.04%
ROIC 7.75%
ROICexc 9.68%
ROICexgc 76.66%
OM 13.43%
PM (TTM) 6.66%
GM 50.62%
FCFM 9.99%
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
ROICexc(3y)9.24%
ROICexc(5y)8.74%
ROICexgc(3y)70.2%
ROICexgc(5y)59.95%
ROCE(3y)11.59%
ROCE(5y)10.94%
ROICexgc growth 3Y20.15%
ROICexgc growth 5Y16.9%
ROICexc growth 3Y6.6%
ROICexc growth 5Y4.3%
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 5.29
Debt/EBITDA 2.46
Cap/Depr 77.86%
Cap/Sales 3.87%
Interest Coverage 21.06
Cash Conversion 75.3%
Profit Quality 150.06%
Current Ratio 0.9
Quick Ratio 0.75
Altman-Z 2.36
F-Score7
WACC6.33%
ROIC/WACC1.22
Cap/Depr(3y)69.82%
Cap/Depr(5y)67.75%
Cap/Sales(3y)3.44%
Cap/Sales(5y)3.55%
Profit Quality(3y)197.16%
Profit Quality(5y)188.14%
High Growth Momentum
Growth
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
EPS Next Y7.51%
EPS Next 2Y7.63%
EPS Next 3Y7.85%
EPS Next 5Y7.81%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%
Revenue Next Year2.65%
Revenue Next 2Y3.28%
Revenue Next 3Y3.54%
Revenue Next 5Y4.25%
EBIT growth 1Y3.01%
EBIT growth 3Y2.73%
EBIT growth 5Y1.96%
EBIT Next Year36.75%
EBIT Next 3Y14.85%
EBIT Next 5Y11.54%
FCF growth 1Y-6.26%
FCF growth 3Y9.25%
FCF growth 5Y6.33%
OCF growth 1Y-1.31%
OCF growth 3Y8.46%
OCF growth 5Y4.96%

DANONE / BSN.DE Fundamental Analysis FAQ

What is the fundamental rating for BSN stock?

ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.


What is the valuation status for BSN stock?

ChartMill assigns a valuation rating of 4 / 10 to DANONE (BSN.DE). This can be considered as Fairly Valued.


How profitable is DANONE (BSN.DE) stock?

DANONE (BSN.DE) has a profitability rating of 7 / 10.


What is the earnings growth outlook for DANONE?

The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 7.51% in the next year.


Is the dividend of DANONE sustainable?

The dividend rating of DANONE (BSN.DE) is 6 / 10 and the dividend payout ratio is 75.94%.